FOXD1 was also recognized as a cancer‐promoter in various human malignancies, such as melanoma (Wu et al., 2018), lung cancer (Li et al., 2018), glioma (Cheng et al., 2016), colorectal cancer (Zhang et al., 2018), and breast cancer (Zhao et al., 2015). This evidence concerns the gene FOXD1 and lung carcinoma.